<DOC>
	<DOC>NCT01465633</DOC>
	<brief_summary>The purpose of this study is to measure the area under the curve (AUC0-48h; extent of systemic availability) and the maxi-mum concentrations (Cmax) of total serum levothyroxine (TT4, bound and free fraction) after a single pharmacological dose of 600 μg administered as tablets also containing iodine supple-ments vs. the same dose of levothyroxine administered as a reference solution without iodine.</brief_summary>
	<brief_title>Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg/ 75 μg Tablets</brief_title>
	<detailed_description />
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Euthyroid men Age: 18 50 Normal values for fT4 und TSH Good state of health Thyroid function disorders in terms of subclinical or overt hyper or hypothyroidism History of thyroid function disorders Focal or diffuse autonomies of the thyroid gland Thyroid nodules &gt;1 ml according to sonographic examination Any acute or chronic illness Dermatitis herpetiformis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>levothyroxine</keyword>
</DOC>